share_log

Rayont Inc- RAYT- Reports 10-Q for the Six-Month Ending December 31, 2021, Financial Results.

Rayont Inc- RAYT- Reports 10-Q for the Six-Month Ending December 31, 2021, Financial Results.

Rayont Inc-RAYT-報告截至2021年12月31日的6個月的10-Q財務業績。
GlobeNewswire ·  2022/02/24 22:07

Palo Alto, California, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international healthcare company specializing in the manufacturing, distribution of alternative medicine products and services across the entire value chain, today reported financial results for the six-month ended December 31, 2021.

加利福尼亞州帕洛阿爾託,2022年2月24日(Global Newswire)--Rayont Inc.(“Rayont”or“Company”)(場外交易市場代碼:RAYT)是一家專門在整個價值鏈上製造、分銷替代醫學產品和服務的國際醫療保健公司,該公司今天公佈了截至2021年12月31日的6個月的財務業績。

Business Highlights Within the Six-Month ended December 31, 2021:

內部業務亮點-截至上月(二零二零年十二月三十一日)1:

Ms. Marshini Moodley, Director and CFO, said, "We recorded improvements across most aspects of the business for the period ending December 31, 2021 compared to same period last year. The key highlight for the last three months is moving into "a state of the art manufacturing facility at 32 French Avenue , Brendale in Brisbane Australia " and our ability to maintain the quarterly revenues despite downtime in production."

董事首席財務官馬什尼·穆德利女士説:“與去年同期相比,我們在截至2021年12月31日的一段時間裏,業務的大部分方面都有所改善。過去三個月的主要亮點是搬進了‘位於澳大利亞布里斯班布倫代爾法蘭西大道32號的最先進的製造工廠’,以及我們在停產的情況下仍能保持季度收入的能力。”

Six-month Ending December 31, 2021, Financial Results:

-月末(二零二零年十二月三十一日)1,財務業績:

    Six Months Ended December 31,  
    2021     2020  
Revenues   $ 1,361,887     $ 1,196,240  
Gross Profit   $ 690,466     $ 524,790  
截至的月份十二月 31,
2021 2020
收入 $ 1,361,887 $ 1,196,240
毛利 $ 690,466 $ 524,790

Improved Balance Sheet Results

資產負債表業績改善

      December 31,
2021
      June 30,
2021
 
Cash   $ 8,320     $ 243,610  
Total Assets   $ 7,955,972     $ 7,157,352  
Total Liabilities   $ 3,607,299     $ 3,430,326  
Total Stockholders' Equity   $ 4,348,673     $ 3,727,026  
十二月31,
2021
六月三十日,
2021
現金 $ 8,320 $ 243,610
總資產 $ 7,955,972 $ 7,157,352
總負債 $ 3,607,299 $ 3,430,326
股東權益總額 $ 4,348,673 $ 3,727,026

Marshini Moodley added, "Our 10-Q performance reflecting increased revenues, total asset portfolio and total stockholders' equity. The debt ratio is decreased from 48% that was on June 30, 2021, to 45% as of December 31, 2021. Our cash reserves have decreased due to capital investments and servicing short term loan interest. The focus this quarter is to refinance the properties from short term loans with private lenders to long term loans with competitive interest rates."

Marshini Moodley補充説,“我們的10-Q業績反映了收入、總資產組合和總股東權益的增加。負債率從2021年6月30日的48%下降到2021年12月31日的45%。由於資本投資和償還短期貸款利息,我們的現金儲備有所減少。本季度的重點是以有競爭力的利率對物業進行再融資,從私人貸款人的短期貸款轉向長期貸款。”

Strategies for Growth

增長戰略

During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:

在本財政年度,我們繼續開展旨在改善Rayont Inc.整體業績的幾項關鍵活動,即:

  • Seek to acquire revenue and profit producing complementary business to Prema Life Australia. This would improve the utilization of increased capacity.
  • Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
  • Launch Rayont Coin as global reward platform for our consumers aimed to enhance customer experience and loyalty.
  • Start operations of Prema Life USA aimed to grow overall revenues and expand into the USA market.
  • 尋求獲得收入和利潤,生產澳大利亞普雷馬人壽的補充業務。這將提高增加的產能的利用率。
  • 為全球自然療法推出Health Script遠程保健平臺,主要市場集中在澳大利亞和美國。
  • 推出Rayont Coin作為我們消費者的全球獎勵平臺,旨在提升客户體驗和忠誠度。
  • Prema Life USA的初創業務旨在增加整體收入,並向美國市場擴張。

These activities are being worked on and we will communicate their completions as we achieve them.

這些活動正在進行中,我們將在完成後通報它們的完成情況。

About Rayont Inc.

A回合賽人造絲Inc.

Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on healthcare including the manufacturing, distribution of alternative medicine products and services across the entire value chain.

Rayont,Inc.(RAYT)是一家自2011年成立以來在美國內華達州註冊的上市公司。2018年,該公司重新定位,專注於醫療保健,包括在整個價值鏈上製造、分銷替代醫學產品和服務。

Longer term, it has also invested in a groundbreaking cancer treatment technology through an exclusive license arrangement for the Sub-Saharan African territories.

從長遠來看,它還通過撒哈拉以南非洲領土的獨家許可安排投資了一項突破性的癌症治療技術。

Headquartered in Australia with expanding operations internationally, Rayont`s purpose is "Making Natural Products to Improve People`s Health". We do this by investing in early research and development, establishing high quality manufacturing assets for regional distribution and operating across the alternative medicine value chain.

總部設在澳大利亞,並在國際上拓展業務,雷揚特的宗旨是“製造天然產品,增進人們的健康”。我們通過投資於早期研發、建立用於區域分銷的高質量製造資產以及跨替代藥物價值鏈運營來做到這一點。

Our underlying strategy is to grow organically, selectively acquire, scale profitable assets and improve efficiency through digitalization.

我們的基本戰略是通過數字化實現有機增長、有選擇地收購、擴大盈利資產規模並提高效率。

For further information, please visit 

欲瞭解更多信息,請訪問

SAFE HARBOR

安全港

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

本新聞稿中的某些陳述可能包含1933年“證券法”第175條規定的前瞻性信息,受1934年“證券交易法”第3b-6條的約束,並受這些規定所創造的安全港的約束。本新聞稿中包含的除事實陳述外的所有陳述,包括但不限於有關公司潛在未來計劃和目標的陳述,均為前瞻性陳述,涉及風險和不確定因素。不能保證這樣的陳述將被證明是準確的,其他結果和進一步的事件可能與這些陳述中預期的大不相同。未來的事件和實際結果可能與前瞻性陳述中陳述的、預期的或潛在的大不相同。

Company Contact:
Investor Relations
ir@rayont.com

公司聯繫人:
投資者關係
郵箱:ir@rayont.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論